← All trials
NCT01939236
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2010
- Primary completion
- Aug 31, 2012
- Completion date
- Sep 30, 2012
- First posted
- Sep 11, 2013
- Last posted
- Oct 10, 2013
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Peking UniversityStudy chair
- Peking UniversityStudy director
- Peking UniversityCollaborator
- Hubei University of Chinese MedicineCollaborator
- Wuhan UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Peking UniversitySponsor investigator
- Changchun University of Chinese MedicineCollaborator
- Peking UniversityOfficial
- Yichang Hospital of Traditional Chinese MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.